TOKYO/TAIPEI – October 13, 2025 – MetaTech (AP) Inc. (TWSE: 3224), a leading Taiwanese biotech AI technology company, and CM Plus, a multinational enterprise specializing in high-standard engineering management and regulatory compliance (headquartered in Singapore and Yokohama, Japan), have signed a Memorandum of Understanding (MOU) to jointly build a new cross-border platform for accelerating biotech product market entry between Taiwan and Japan.
The partnership will integrate MetaTech’s advanced AI-driven GMP document generation technology with CM Plus’s established regulatory and virtual pharmaceutical capabilities in Japan. Together, the two companies aim to provide a comprehensive, high-efficiency support system for pharmaceutical and biotech firms seeking to enter each other’s markets, while also expanding into broader Asian markets.
This collaboration carries both strategic and symbolic significance. CM Plus’s founder and Group CEO, Mr. Tsunehiro Togashi, is a descendant of a 14th-generation samurai family. MetaTech’s proprietary AI platform, named “Neo-Katana,” symbolizes the precision and power of an AI “blade” capable of solving complex GMP documentation challenges with speed and accuracy. The fusion of samurai heritage with cutting-edge AI technology reflects a unique cross-cultural partnership that is both strategic and emblematic.
Under the MOU, both parties will jointly promote their systems focusing on regulatory compliance, GMP documentation, and international market expansion. MetaTech’s AI platform — the first in Taiwan to build a full GMP data model — enables automatic generation of compliant documents, holding algorithm patents in Taiwan and provisional patents in the U.S., Japan, and Europe.
CM Plus, Japan’s first licensed “Virtual Pharmaceutical Company,” provides plant engineering, GMP qualification, and regulatory consulting to guide overseas biotech products through Japan’s approval pathway. The collaboration will also integrate CM Plus’s pharmo.AI regulatory engine and CORRESSA project management system with MetaTech’s AI documentation platform to enhance data integrity and compliance efficiency.
Through this alliance, MetaTech and CM Plus will serve as each other’s exclusive partners in their home markets. MetaTech will support Japanese biotech firms entering Taiwan, while CM Plus will represent MetaTech in Japan and explore opportunities across Southeast Asia.
This MOU marks a strategic alignment between Taiwan’s leading AI biotech innovator and Japan’s premier regulatory service provider, creating a new model for AI-powered GMP and cross-border cooperation in Asia’s biotech industry.
About MetaTech (AP) Inc.
MetaTech (AP) Inc., founded in 1998 and listed in Taiwan since 2004, operates across electronics and regenerative medicine. With patented M-Cell technology and AI-driven innovation, we lead in cell therapies for cartilage, skin, and organ repair. Headquartered in Taiwan, MetaTech serves markets across Asia with a vision to fuse tech and biotech for a healthier future.
About CM Plus group
A global professional firm specializing in facility construction, quality assurance, and GMP education/training. Headquartered in Singapore, with subsidiaries in Japan, Vietnam, and Indonesia, the Group is strategically expanding its industry expertise in pharmaceuticals, medical devices, regenerative medicine, and general industries, including data centers, as well as expanding its offerings in AI/DX.
To learn more, visit
METATECH (AP) INC.
https://www.metatech.com.tw/en
Media Contact
Company Name: METATECH (AP) INC.
Contact Person: Stacy Yu
Email: Send Email
Country: Taiwan
Website: https://www.metatech.com.tw/en